Interleukin 17 alone is not a discriminant biomarker in early demyelinating spectrum disorders.
OBJECTIVES: We investigate levels of IL-17 in serum and CSF in patients diagnosed at different stages of demyelinating diseases (RIS, CIS, relapsing remitting (RR) or active multiple sclerosis patients:AMS) as a marker of inflammatory condition. J Neurol Sci. 2016 Sep 15;368:334-6. … Lire la suite …